Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs Revvity Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $15.33 (market cap $1.93B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 8.8× Abrdn Physical Platinum Shares ETF's market cap, and Revvity Inc pays a 0.18% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 42 Days and Revvity Inc for 12 Days on average.
| PPLT | RVTY | |
|---|---|---|
Market Cap | $1.93B | $16.98B |
Volume | 1,698,523 | 1,456,900 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $157.36 |
52-Week Low | $13.73 | $82.26 |
Typical Hold Time | 42 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, is trading at $14.78, down 4.46% with a bearish technical outlook. Moving averages and oscillators signal selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights platinum's underperformance in the precious metals rally, with technical and fundamental signals pointing to continued weakness despite historical seasonal patterns.
The outlook remains cautious with bearish momentum dominating. Investment opportunity exists for contrarian investors betting on a catch-up trade in platinum, but risks include sustained supply contango and weak relative performance versus gold and silver. Key catalysts would be renewed industrial demand or shifts in precious metals sentiment.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
